Codexis, Inc. has completed a public offering of common stock, issuing 16.7 million shares at $1.50 per share on July 27, 2026. The biotechnology company received net proceeds of approximately $23.1 million after deducting underwriting fees and expenses. The offering was underwritten by Piper Sandler & Co. and Cantor Fitzgerald & Co., with underwriters retaining a 30-day option to purchase an additional 2.5 million shares.

Key Points

  • NASDAQ: CDXS
  • Codexis completed a public offering of 16.7 million shares of common stock on July 27, 2026
  • Offering price of $1.50 per share; net proceeds of approximately $23.1 million after fees and expenses
  • Underwriters hold a 30-day option to purchase up to 2.5 million additional shares at the same price
  • Company and executives subject to 90-day lock-up agreement preventing share sales without underwriter consent

Offering Structure and Pricing Details

Codexis entered into an underwriting agreement on July 23, 2026, with Piper Sandler & Co. and Cantor Fitzgerald & Co. serving as representatives of the underwriting syndicate. The company agreed to issue and sell 16.7 million shares of common stock to the underwriters at a fixed public offering price of $1.50 per share. This pricing structure established the baseline valuation for the company's equity capital raise during the offering period.

As part of the underwriting terms, the Underwriters were granted a 30-day option to purchase up to an additional 2.5 million shares of Common Stock, exercisable from the closing date. This over-allotment option, commonly known as a "green shoe," is standard in equity offerings and provides the underwriters with flexibility to stabilize the stock price and meet demand in the secondary market following the offering's completion.

Net Proceeds and Capital Raise Implications

Upon closing of the offering on July 27, 2026, Codexis received net proceeds of approximately $23.1 million. This figure reflects the gross proceeds from the sale of 16.7 million shares, reduced by the underwriters' discounts and commissions as well as estimated offering expenses paid by the company. The net proceeds represent the capital available to Codexis for operations, research and development, or other corporate purposes as determined by management.

The capital raised through this offering provides the company with liquid resources to fund its business operations and strategic initiatives. Investors should monitor subsequent filings and earnings announcements for disclosure regarding how management intends to deploy these funds and their impact on the company's financial position and operational capability.

Lock-up Agreement and Trading Restrictions

Codexis, along with all of its directors and executive officers, agreed to a 90-day lock-up restriction beginning on July 23, 2026, the date the underwriting agreement was executed. Under this agreement, restricted parties cannot sell, transfer, or otherwise dispose of shares of Common Stock held by them without obtaining prior written consent from the Representatives on behalf of the Underwriters. This restriction is designed to prevent large insider sales from destabilizing the stock price immediately following the public offering.

The lock-up agreement contains certain exceptions, which are described in detail in the prospectus supplement filed with the Securities and Exchange Commission. These exceptions typically include sales pursuant to Rule 10b5-1 trading plans adopted before the announcement, sales to satisfy tax obligations, or other specific circumstances as agreed by the underwriters. The filing indicates that a full description of these exceptions can be found in the prospectus supplement rather than being enumerated in the current disclosure.

Underwriting Syndicate Composition

The offering was managed by Piper Sandler & Co. and Cantor Fitzgerald & Co., which served jointly as representatives of the underwriting syndicate. These firms were responsible for organizing the offering, purchasing the securities from Codexis, and reselling them to public investors. The selection of two co-representatives suggests a substantial underwriting syndicate was assembled to distribute the shares to institutional and retail investors.

Under the terms of the Underwriting Agreement, Codexis agreed to indemnify the Underwriters against certain liabilities arising under the Securities Act of 1933, as amended, or to contribute to payments the Underwriters might be required to make as a result of such liabilities. This indemnification is standard in equity offerings and protects the underwriters from losses related to misstatements or omissions in the offering documents.

Regulatory Framework and Registration Status

The offering was conducted under a shelf registration statement on Form S-3 with Registration No. 333-279082, which was previously declared effective by the Securities and Exchange Commission. This registration statement allows Codexis to offer securities to the public without requiring a new registration statement for each offering, provided the offerings meet specific criteria regarding the company's status and financial metrics. The use of a shelf registration streamlines the process for public companies to raise capital efficiently.

A prospectus supplement and accompanying prospectus were filed with the SEC pursuant to the effective shelf registration statement. These documents contain detailed information about the offering, the company, its business, risk factors, and financial information necessary for investors to make informed decisions. The prospectus supplement specifically addresses the terms of the July 2026 offering, while the base prospectus contains more general information about Codexis and its operations.

Legal Opinion and Documentation

Latham & Watkins LLP, a prominent securities and corporate law firm, provided a legal opinion regarding the validity of the securities issued in the offering. This opinion, filed as Exhibit 5.1 to the current report, confirms that the shares issued have been validly issued and are fully paid and non-assessable. Legal opinions of this nature are a standard requirement in public equity offerings and provide assurance to investors regarding the legal status of the securities they are purchasing.

The underwriting agreement itself, dated July 23, 2026, was filed as an exhibit to the current report and is incorporated by reference. This document contains the complete terms and conditions of the offering, including representations and warranties made by Codexis, the compensation and indemnification provisions applicable to the Underwriters, and the conditions to closing. Investors and analysts can review the full agreement to understand the complete structure and terms of the transaction.

Timing of Offering Announcement and Completion

The underwriting agreement was signed on July 23, 2026, initiating the offering process. The offering closed and the company completed the sale and issuance of all 16.7 million shares on July 27, 2026, four business days after the agreement was executed. This relatively quick closing timeline reflects efficient execution by the underwriting syndicate and regulatory approval of the prospectus supplement.

The filing disclosing these events was dated July 27, 2026, the same date the offering closed, providing investors and market participants with contemporaneous notification of the completed capital raise. This timely disclosure ensures that public shareholders and potential investors have accurate information regarding the company's capital structure and the newly issued shares.

Capital Structure Impact and Share Dilution Considerations

The issuance of 16.7 million shares represents a significant increase in the number of outstanding shares of Codexis common stock. Existing shareholders should note that this offering results in dilution of their ownership percentage in the company unless they participated in the offering. The extent of dilution depends on the total number of shares outstanding before the offering, which is not disclosed in this particular filing.

Investors analyzing the impact of this offering on earnings per share and other per-share metrics should account for the newly issued shares in their calculations. The company may provide updated share count information in subsequent quarterly and annual filings. Additionally, the potential exercise of the underwriters' over-allotment option to purchase up to 2.5 million additional shares could further increase the share count if that option is exercised during the 30-day period following closing.

Future Monitoring Points for Investors

Investors should monitor Codexis's upcoming quarterly and annual filings to understand how management deploys the approximately $23.1 million in net proceeds. These filings will provide insight into whether the funds are used for research and development initiatives, working capital, strategic acquisitions, debt repayment, or other corporate purposes. Management guidance regarding capital allocation strategies may be disclosed in earnings calls, investor presentations, or subsequent regulatory filings.

Additionally, investors should track whether the underwriters exercise their over-allotment option to purchase the additional 2.5 million shares. If exercised in full, this would bring the total shares issued from the offering to 19.2 million. The exercise of this option, if it occurs, will be reflected in future regulatory filings and will further impact the company's share count and per-share metrics. The 90-day lock-up period expiring in late October 2026 may also be a point of observation for market participants monitoring insider selling patterns.